These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 21252462)
1. Assessment of effectiveness and safety of Ibicella lutea extract in the control of experimental Proteus mirabilis urinary tract infection. Sosa V; Zunino P J Infect Dev Ctries; 2010 Dec; 4(12):814-21. PubMed ID: 21252462 [TBL] [Abstract][Full Text] [Related]
2. Effect of Ibicella lutea on uropathogenic Proteus mirabilis growth, virulence, and biofilm formation. Sosa V; Zunino P J Infect Dev Ctries; 2009 Dec; 3(10):762-70. PubMed ID: 20009277 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of Proteus mirabilis structural fimbrial proteins as antigens against urinary tract infections. Pellegrino R; Galvalisi U; Scavone P; Sosa V; Zunino P FEMS Immunol Med Microbiol; 2003 May; 36(1-2):103-10. PubMed ID: 12727373 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of Acacia nilotica aqueous extract in treating biofilm-forming and multidrug resistant uropathogens isolated from patients with UTI syndrome. Elamary RB; Albarakaty FM; Salem WM Sci Rep; 2020 Jul; 10(1):11125. PubMed ID: 32636429 [TBL] [Abstract][Full Text] [Related]
6. Vaccines for Proteus mirabilis in urinary tract infection. Li X; Mobley HL Int J Antimicrob Agents; 2002 Jun; 19(6):461-5. PubMed ID: 12135833 [TBL] [Abstract][Full Text] [Related]
7. Preventive and therapeutic administration of an indigenous Lactobacillus sp. strain against Proteus mirabilis ascending urinary tract infection in a mouse model. Fraga M; Scavone P; Zunino P Antonie Van Leeuwenhoek; 2005 Jul; 88(1):25-34. PubMed ID: 15928974 [TBL] [Abstract][Full Text] [Related]
8. Nasal immunization with attenuated Salmonella Typhimurium expressing an MrpA-TetC fusion protein significantly reduces Proteus mirabilis colonization in the mouse urinary tract. Scavone P; Umpiérrez A; Maskell DJ; Zunino P J Med Microbiol; 2011 Jul; 60(Pt 7):899-904. PubMed ID: 21415205 [TBL] [Abstract][Full Text] [Related]
9. Vaccination to Protect Against Proteus mirabilis Challenge Utilizing the Ascending Model of Urinary Tract Infection. Smith SN; Himpsl SD; Mobley HLT Methods Mol Biol; 2019; 2021():201-215. PubMed ID: 31309507 [TBL] [Abstract][Full Text] [Related]
10. Native flagellin does not protect mice against an experimental Proteus mirabilis ascending urinary tract infection and neutralizes the protective effect of MrpA fimbrial protein. Scavone P; Umpiérrez A; Rial A; Chabalgoity JA; Zunino P Antonie Van Leeuwenhoek; 2014 Jun; 105(6):1139-48. PubMed ID: 24771125 [TBL] [Abstract][Full Text] [Related]
11. Proteus mirabilis urinary tract infection and bacteremia: risk factors, clinical presentation, and outcomes. Chen CY; Chen YH; Lu PL; Lin WR; Chen TC; Lin CY J Microbiol Immunol Infect; 2012 Jun; 45(3):228-36. PubMed ID: 22572004 [TBL] [Abstract][Full Text] [Related]
12. Vaccination with proteus toxic agglutinin, a hemolysin-independent cytotoxin in vivo, protects against Proteus mirabilis urinary tract infection. Alamuri P; Eaton KA; Himpsl SD; Smith SN; Mobley HL Infect Immun; 2009 Feb; 77(2):632-41. PubMed ID: 19029299 [TBL] [Abstract][Full Text] [Related]
13. Catalase Activity is Critical for Proteus mirabilis Biofilm Development, Extracellular Polymeric Substance Composition, and Dissemination during Catheter-Associated Urinary Tract Infection. White AN; Learman BS; Brauer AL; Armbruster CE Infect Immun; 2021 Sep; 89(10):e0017721. PubMed ID: 34280035 [TBL] [Abstract][Full Text] [Related]
14. [Proteus mirabilis isolated from urine, resistance to antibiotics and biofilm formation]. Cernohorská L; Chvílová E Klin Mikrobiol Infekc Lek; 2011 Jun; 17(3):81-5. PubMed ID: 21780025 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of inhibitory activity of domestic probiotics for against invasion and infection by Proteus mirabilis in the urinary tract. Lai TM; Lin PP; Hsieh YM; Tsai CC J Infect Dev Ctries; 2020 Apr; 14(4):366-372. PubMed ID: 32379713 [TBL] [Abstract][Full Text] [Related]
16. A Unique Case of Community Acquired Proteus mirabilis Meningitis. Hamid K; Hamza M; Naim T; Shahid M; Hsu JL S D Med; 2022 Aug; 75(8):357-360. PubMed ID: 36745983 [TBL] [Abstract][Full Text] [Related]
17. Proteus mirabilis uroepithelial cell adhesin (UCA) fimbria plays a role in the colonization of the urinary tract. Pellegrino R; Scavone P; Umpiérrez A; Maskell DJ; Zunino P Pathog Dis; 2013 Mar; 67(2):104-7. PubMed ID: 23620155 [TBL] [Abstract][Full Text] [Related]
18. Nitroxoline: an option for the treatment of urinary tract infection with multi-resistant uropathogenic bacteria. Hof H; Juretschke C Infection; 2019 Jun; 47(3):493-495. PubMed ID: 30449013 [TBL] [Abstract][Full Text] [Related]
19. A novel multi-peptide subunit vaccine admixed with AddaVax adjuvant produces significant immunogenicity and protection against Proteus mirabilis urinary tract infection in mice model. Choubini E; Habibi M; Khorshidi A; Ghasemi A; Asadi Karam MR; Bouzari S Mol Immunol; 2018 Apr; 96():88-97. PubMed ID: 29525454 [TBL] [Abstract][Full Text] [Related]
20. Clonal relatedness of Proteus mirabilis strains causing urinary tract infections in companion animals and humans. Marques C; Belas A; Aboim C; Trigueiro G; Cavaco-Silva P; Gama LT; Pomba C Vet Microbiol; 2019 Jan; 228():77-82. PubMed ID: 30593384 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]